Affinity Biosensors announced that George Goedesky has joined its team as Vice President of Sales and Marketing.  He will lead the rollout of the LifeScale AST system for rapid antibiotic susceptibility tests, now in U.S. clinical trials for identifying targeted therapy for sepsis.  George has extensive experience introducing ground-breaking diagnostic technologies that have achieved wide adoption and significant impact on patient care.  Most recently, he led the adoption of the Bruker MALDI Biotyper (MBT) platform in the Americas. Ken Babcock, CEO of Affinity Biosensors, commented: “We are thrilled to have George leading the introduction of LifeScale AST in the U.S. clinical microbiology market.  He brings an exemplary track record of success, a deep understanding of the clinical utility of new diagnostics, and extensive contacts with leading microbiologists and hospitals.  Most of all, it’s George’s passion for improving patient care by introducing game-changing technologies that make him a perfect fit with our effort to revolutionize rapid susceptibility testing with LifeScale AST.” George Goedesky commented: “I am very excited to be joining the Affinity Biosensors team.  Their deep expertise in mass sensing technologies has resulted ...

Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test Challenge – CCC Innovation Center  Affinity Biosensors Ultra-Rapid Phenotypical AST by Microbe Mass Measurement has been selected as a Step 1 semifinalist in the Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test Challenge by the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for Preparedness and Response (ASPR). The federal prize competition will award up to a total of $20 million in prizes, subject to the availability of funds, for innovative rapid, point-of-need diagnostic tests to combat the emergence and spread of drug resistant bacteria.

Affinity Biosensors has been awarded an R&D 100 award for the LifeScale-R Instrument. LifeScale’s ability to detect microbial growth earlier than any other commercial technique enables the instrument to be used for both fundamental research, measuring microbial growth and response, or to determine antimicrobial susceptibility in under three hours. A three-hour susceptibility test will allow antibiotic treatment to be tailored to the infection sooner, in some cases by as much as 24 hours.

  The LifeScale-AST has received a CE Mark (IVDD 98/79/EC) for Antimicrobial Susceptibility Tests direct from positive blood culture. For more information contact Affinity Biosensors. The LifeScale-AST instrument is not currently available in the USA.